Literature DB >> 24570913

Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?

James Fung1, Ching-Lung Lai1, Man-Fung Yuen1, Irene Oi-Lin Ng2.   

Abstract

Entities:  

Year:  2013        PMID： 24570913      PMCID： PMC3924639          DOI： 10.3978/j.issn.2304-3881.2012.10.04

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

1.  Statin use and the risk of liver cancer: a population-based case–control study.

Authors:  Hui-Fen Chiu; Shu-Chen Ho; Chih-Cheng Chen; Chun-Yuh Yang
Journal:  Am J Gastroenterol       Date:  2010-12-14       Impact factor: 10.864

2.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

Authors:  Yu-Tse Tsan; Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

3.  Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells.

Authors:  Borna Relja; Frank Meder; Kerstin Wilhelm; Dirk Henrich; Ingo Marzi; Mark Lehnert
Journal:  Int J Mol Med       Date:  2010-11       Impact factor: 4.101

4.  Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.

Authors:  Andreas P Sutter; Kerstin Maaser; Michael Höpfner; Alexander Huether; Detlef Schuppan; Hans Scherübl
Journal:  J Hepatol       Date:  2005-05-31       Impact factor: 25.083

5.  Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK.

Authors:  Borna Relja; Frank Meder; Minhong Wang; Roman Blaheta; Dirk Henrich; Ingo Marzi; Mark Lehnert
Journal:  Int J Oncol       Date:  2010-12-28       Impact factor: 5.650

6.  Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.

Authors:  Ted Bader; Brent Korba
Journal:  Antiviral Res       Date:  2010-03-06       Impact factor: 5.970

7.  Cancer risk among statin users: a population-based cohort study.

Authors:  Søren Friis; Aslak H Poulsen; Søren P Johnsen; Joseph K McLaughlin; Jon P Fryzek; Susanne O Dalton; Henrik T Sørensen; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

8.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.

Authors:  Hashem B El-Serag; Michael L Johnson; Christine Hachem; Robert O Morgana
Journal:  Gastroenterology       Date:  2009-01-30       Impact factor: 22.682

10.  Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Authors:  Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai
Journal:  Antivir Ther       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.